Author

Hélène Grosjean

Observed names: Grosjean H, H. Grosjean, H.A.I. Grosjean

Institution: University of Calgary

Observed institutions: University of Calgary, Hôpital de la Timone

OpenAlex ID: A5111064768

Clinical manifestations of intermediate allele carriers in Huntington disease

2016 · Esther Cubo, María A. Ramos-Arroyo, et al. · Neurology · 53

Reduced Cancer Incidence in Huntington’s Disease: Analysis in the Registry Study

2018 · Paul McNulty, Richard Pilcher, et al. · Journal of Huntington s Disease · 35

425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents

2020 · C.L. Gan, D.E. Meyers, et al. · Annals of Oncology · 4

EP08.04-01 Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab

2023 · C.A. Lim, S. Ghosh, et al. · Journal of Thoracic Oncology

P09.08 Age-Related Outcomes of First-Line Pembrolizumab in a Real-World Non-Small-Cell Lung Cancer (NSCLC) Cohort

2021 · S. Dolter, H. Grosjean, et al. · Journal of Thoracic Oncology

1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials

2020 · C.L. Gan, I. Stukalin, et al. · Annals of Oncology

Works count: 7

Citation count: 92

H-index: 3

I10-index: 2